Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA21004 vs placebo and duloxetine in acute treatment of Major Depressive Disorder
2009-017523-26Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in MADRS total score at Week 8. Started Mar 2010; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2009-017523-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017523-26.